Treatment with carvedilol 6.25 mg twice daily resulted in resolution of chest pain and an optimal quality of life in a 61-year-old West African male with apical hypertrophic cardiomyopathy.
Case Report (n=1)
No
This case highlights the occurrence of apical hypertrophic cardiomyopathy (Yamaguchi syndrome) in a patient of West African descent, a condition typically more prevalent in Asian populations, and its successful management with carvedilol.
Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy. The apical variant, also known as Yamaguchi syndrome, is a rare condition that is reportedly more prevalent in Asian populations. It is characterized by hypertrophy predominantly limited to the left ventricular apex, with a classic "ace of spades" shaped left ventricular cavity. We present a 61-year-old male of West African descent with a chest pain syndrome and deep inverted precordial T-waves on 12-lead electrocardiography. Two-dimensional echocardiography demonstrated focal left ventricular hypertrophy limited to the apex, and speckle-tracking imaging showed reduced apical strain, findings consistent with apical hypertrophic cardiomyopathy (HCM). Risk assessment for sudden cardiac death was low. A previous invasive coronary artery angiography reported normal epicardial coronary arteries. The patient was started on carvedilol 6.25 mg orally twice daily, with resolution of the chest pain and, so far, a generally optimal quality of life after four months of follow-up.
Dzebu et al. (Fri,) conducted a case report in Apical hypertrophic cardiomyopathy (Yamaguchi syndrome) (n=1). Carvedilol was evaluated on Resolution of chest pain and quality of life. Treatment with carvedilol 6.25 mg twice daily resulted in resolution of chest pain and an optimal quality of life in a 61-year-old West African male with apical hypertrophic cardiomyopathy.